China Pharma Holdings (CPHI) has announced that its wholly-owned subsidiary, Hainan Helpson Medical and Biotechnology Co., plans to launch a Dry Eye Disease Therapeutic Device in China during the first quarter of 2025. This medical treatment device, which is protected by patents, targets dry eye disease. The acquisition of this technology was finalized by Helpson at the end of 2022.
Specializing in the pharmaceutical sector, China Pharma Holdings is dedicated to the development, manufacturing, and marketing of a diverse portfolio of products. The company's focus is on conditions with high incidence and mortality rates in China, such as cardiovascular diseases, central nervous system disorders, infectious diseases, and digestive illnesses.
